Vaporox (VHT) is an FDA-cleared wound care solution that uses hydrating vapor and concentrated oxygen to promote rapid healing. Ideal for use in skilled nursing facilities and private practice, to reduce bioburden, stimulate tissue growth, and help improve patient outcomes. When used with standard wound care, Vaporox has consistently healed up to 84% of chronic wounds.

Rockies Venture Club initially invested in Vaporox's Series Seed I round in 2019. Vaporox is currently raising additional capital to support additional sales growth and inventory for new devices.

Join Rockies Venture Club for the Vaporox Investor Update to learn more about the company's progress, meet the executive team, and discuss the opportunity alongside existing RVC investors. The Investor Update will cover all the major due diligence questions such as IP, competition, leadership, funding strategy, exit strategy, use of funds, milestones, etc.